Clinical implications of indapamide sustained release 1.5 mg in hypertension

Clinical Pharmacokinetics

Volumn 37, Issue SUPPL. 1, 1999, Pages 21-32

  Donnelly, Richard ^a,b,c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; POTASSIUM ION;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ORAL DRUG ADMINISTRATION; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SUSTAINED RELEASE FORMULATION; TABLET; TREATMENT PLANNING; VASCULAR DISEASE;

AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; HUMANS; HYPERTENSION; INDAPAMIDE; RISK FACTORS;

EID: 0032849029     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937001-00004     Document Type: Review

References (34)

1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 1997; 157; 2413-46
2. Guidelines Subcommittee. 1999 World Health Organization -International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83
3. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960-1991. Hypertension 1995; 26: 60-9
4. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hypertens 1997; 11: 213-20
5. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16: 747-52
6. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Pt 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38
7. Andersson OK, Almgren T, Persson B, et al. Survival in treated hypertension: follow-up study after two decades. BMJ 1998; 317: 167-71
8. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279; 1903-7
9. Kostis JB, Davis BR, Cutler J, SHEP Co-operative Research Group, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997; 278: 212-6
10. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS (Perindopril Protection against Recurrent Stroke Study). J Hypertens 1996; 14 Suppl. 2; S41-46
11. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-13
12. National High Blood Pressure Education Program Working Group, National High Blood Pressure Education Program Working Group report on hypertension in the elderly. Hypertension 1994; 23: 275-85
13. Madhavan S, Ooi WL, Cohen H, et al. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395-401
14. MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994. J Vase Med Biol 1993; 4: 265-71
15. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomised controlled trials in elderly hypertensives. J Clin Exp Hypertens 1993; 15: 967-78
16. WHO - International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomised trials of blood pressure lowering treatments. J Hypertens 1998; 16: 127-37
17. Leonetti G, Rappelli A, Salvetti A, et al. Long-term effects of indapamide: final results of a 2-year Italian multicenter study in systemic hypertension. Am J Cardiol 1990; 65: 67H-71
18. Chaffman M, Heel RC, Brogden RN, et al. Indapamide: a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1984; 28: 189-235
19. Senior R, Imbs JL, Bory RN, et al. Indapamide reduces hypertensive left ventricular hypertrophy: an international multicentre study. J Cardiovasc Pharmacol 1993; 22: 106-10
20. Carey PA, Sheridan DJ, de Cordoue A, et al. Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis. Am J Cardiol 1996; 77; 17B-19
21. Leonetti G, Rappelli A, Salvetti A, et al. Tolerability and wellbeing with indapamide in the treatment of mild-moderate hypertension. Am J Med 1988; 84 Suppl. 1B: 59-64
22. Ames RP, A comparison of blood lipid and blood pressure responses during treatment of systemic hypertension with indapamide and thiazides. Am J Cardiol 1996; 77: 12B-16
23. Ambrosioni E, Safar M, Degaute J-P, et al. Low-dose antihypertensive therapy with 1.5mg sustained-release indapamide: results of randomised double-blind controlled studies. European Study Group. J Hypertens 1998; 16: 1677-84
24. Mallion J-M, Asmar R, Boutelant S, et al. Twenty-four hour antihypertensive efficacy of indapamide 1.5mg sustained release: results of two randomised double-blind controlled studies. J Cardiovasc Pharmacol 1998; 32: 673-8
25. Omboni S, Parati G, Zanchetti A, et al. Calculation of troughpeak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens 1995; 13: 1105-12
26. Staessen JA, Bieniaszewski L, Bruntinx F, et al. The trough-to-peak ratio as an instrument to evaluate antihypertensive drugs. Hypertension 1995; 26: 942-9
27. Meredith PA, Elliott HL. FDA guide lines on trough : peak ratios in the evaluation of antihypertensive agents. J Cardiovasc Pharmacol 1994; 23: S26-30
28. Bulpitt CJ, Emeriau JP, Knauf H, et al. Equivalence study of antihypertensive effect of indapamide SR 1.5mg, hydrochlorothiazide 25mg and amlodipine 5mg in hypertension [abstract]. J Hypertens 1997; 15 Suppl. 14: S130
29. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predict ing cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-8
30. Dahlof B, Pennert K, Hansson L. Regression of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110
31. Verdecehia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial change in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54
32. Devereux RB. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation 1997; 95: 1983-5
33. Gosse P, Guez D, Gueret P, et al. Centralised echocardiogram quality control in a multicentre study of regression of left ventricular hypertrophy in hypertension. J Hypertens 1998; 16: 531-5
34. Gosse P, Dubourg O, Gueret P, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5mg versus enalapril 20mg: results of LIVE study [abstract]. J Am Coll Cardiol 1999; 33: 246A